Journal
MOLECULAR MEDICINE REPORTS
Volume 16, Issue 6, Pages 7879-7889Publisher
SPANDIDOS PUBL LTD
DOI: 10.3892/mmr.2017.7641
Keywords
platelet-derived growth factor isoforms; hepatic fibrosis; signaling pathway; targeted drug; natural product; synergistic effect
Categories
Funding
- National Natural Science Foundation of China [81573591]
- Zhejiang Science and Technology Foundation [2014F10033, 2015F50056]
- Zhejiang Innovation discipline 'Laboratory Animal Genetic Engineering' [201604]
- Zhejiang Foundation for the Cultivation of High-level Innovative Health Talents [201206]
Ask authors/readers for more resources
The platelet-derived growth factor (PDFG) signaling pathway exerts persistent activation in response to a variety of stimuli and facilitates the progression of hepatic fibrosis. Since this pathway modulates a broad spectrum of cellular processes, including cell growth, differentiation, inflammation and carcinogenesis, it has emerged as a therapeutic target for hepatic fibrosis and liver-associated disorders. The present review exhibits the current knowledge of the role of the PDGF signaling pathway and its pathological profiles in hepatic fibrosis, and assesses the potential of inhibitors which have been investigated in the experimental hepatic fibrosis model, in addition to the clinical challenges associated with these inhibitors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available